BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freeman M, Laks S. Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship. Melanoma Manag. 2019;6:MMT12. [PMID: 31236204 DOI: 10.2217/mmt-2019-0003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Carter TJ, George C, Harwood C, Nathan P. Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease. Eur J Cancer 2022;166:240-53. [PMID: 35325701 DOI: 10.1016/j.ejca.2022.02.016] [Reference Citation Analysis]
2 Guerrisi A, Russillo M, Loi E, Ganeshan B, Ungania S, Desiderio F, Bruzzaniti V, Falcone I, Renna D, Ferraresi V, Caterino M, Solivetti FM, Cognetti F, Morrone A. Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach. Front Oncol 2021;11:704607. [PMID: 34692481 DOI: 10.3389/fonc.2021.704607] [Reference Citation Analysis]
3 Thorpe RB, Covington KR, Caruso HG, Quick AP, Zolochevska O, Bricca GM, Campoli M, DeBloom JR Jr, Fazio MJ, Greenhaw BN, Kirkland EB, Machan ML, Brodland DG, Zitelli JA. Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following Mohs micrographic surgery. J Am Acad Dermatol 2021:S0190-9622(21)02854-1. [PMID: 34808324 DOI: 10.1016/j.jaad.2021.10.062] [Reference Citation Analysis]
4 Iacullo J, Barriera-Silvestrini P, Knackstedt TJ. Dermatologic Follow-up and Assessment of Suspicious Lesions. Clin Plast Surg 2021;48:617-29. [PMID: 34503722 DOI: 10.1016/j.cps.2021.05.006] [Reference Citation Analysis]
5 Jaeger ZJ, Williams GA, Chen L, Mhlanga JC, Cornelius LA, Fields RC. 18 F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma. J Surg Oncol 2021. [PMID: 34741547 DOI: 10.1002/jso.26737] [Reference Citation Analysis]
6 Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol 2020;83:745-53. [PMID: 32229276 DOI: 10.1016/j.jaad.2020.03.053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
7 Dillon LD, McPhee M, Davidson RS, Quick AP, Martin B, Covington KR, Zolochevska O, Cook RW, Vetto JT, Jarell AD, Fleming MD. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. Curr Med Res Opin 2022;:1-21. [PMID: 35081854 DOI: 10.1080/03007995.2022.2033560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dubin DP, Dinehart SM, Farberg AS. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma. Am J Clin Dermatol 2019;20:763-70. [PMID: 31359351 DOI: 10.1007/s40257-019-00464-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bleicher J, Cohan JN, Huang LC, Peche W, Pickron TB, Scaife CL, Bowles TL, Hyngstrom JR, Asare EA. Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature. World J Gastroenterol 2021; 27(3): 267-280 [PMID: 33519141 DOI: 10.3748/wjg.v27.i3.267] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer 2021;127:2251-61. [PMID: 33826754 DOI: 10.1002/cncr.33483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
11 Ravichandran S, Nath N, Jones DC, Li G, Suresh V, Brys AK, Hanks BA, Beasley GM, Salama AKS, Howard BA, Mosca PJ. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. Surg Oncol 2020;35:533-9. [PMID: 33161362 DOI: 10.1016/j.suronc.2020.10.018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Aaberg TM, Covington KR, Tsai T, Shildkrot Y, Plasseraud KM, Alsina KM, Oelschlager KM, Monzon FA. Gene Expression Profiling in Uveal Melanoma: Five-Year Prospective Outcomes and Meta-Analysis. Ocul Oncol Pathol 2020;6:360-7. [PMID: 33123530 DOI: 10.1159/000508382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Fiedorowicz M, Wieteska M, Rylewicz K, Kossowski B, Piątkowska-janko E, Czarnecka AM, Toczylowska B, Bogorodzki P. Hyperpolarized 13C tracers: Technical advancements and perspectives for clinical applications. Biocybernetics and Biomedical Engineering 2021;41:1466-85. [DOI: 10.1016/j.bbe.2021.03.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Newcomer K, Robbins KJ, Perone J, Hinojosa FL, Chen D, Jones S, Kaufman CK, Weiser R, Fields RC, Tyler DS. Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. Curr Probl Surg 2022;59:101030. [PMID: 35033317 DOI: 10.1016/j.cpsurg.2021.101030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Vietti Violi N, Hajri R, Haefliger L, Nicod-Lalonde M, Villard N, Dromain C. Imaging of Oligometastatic Disease. Cancers (Basel) 2022;14:1427. [PMID: 35326586 DOI: 10.3390/cancers14061427] [Reference Citation Analysis]
16 Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA, Bowles TL, Hyngstrom JR. Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. J Surg Oncol 2020;122:1770-7. [PMID: 33098702 DOI: 10.1002/jso.26214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]